Insulin Potentiation Therapy

This policy addresses insulin potentiation therapy (IPT) — proposed for cancer and other conditions (e.g., chronic degenerative diseases) — and specifies there are no covered indications. IPT is considered experimental, investigational and not medically necessary and is not covered (NCCN does not recommend it); coverage is subject to the member’s benefit plan and local Medicare carrier discretion and the policy does not supersede contract limitations.

"Insulin potentiation therapy (IPT) is considered experimental, investigational and/or unproven and is not covered."

Sign up to see full coverage criteria, indications, and limitations.